Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023

On the surface, macular degeneration treatment Eylea continued its juggernaut path in 2022. On Tuesday, when Bayer reported fourth quarter earnings, it showed 3.2 billion euros ($3.4 billion) in full-year sales for a 10% increase on the previous year.